Celyad Announces October and November 2019 Investor Conference Schedule

Celyad Announces October and November 2019 Investor Conference Schedule

Celyad to Present Update on mCRC Clinical Program at the 2019 SITC Annual Meeting

Celyad to Present Update on mCRC Clinical Program at the 2019 SITC Annual Meeting

Celyad Announces Closing of $20 Million Global Offering

Celyad Announces Closing of $20 Million Global Offering

Understanding the expression profile of NKG2D ligands on T cells: Implications for CAR T cell therapy

Understanding the expression profile of NKG2D ligands on T cells: Implications for CAR T cell therapy

The targeted knockdown of CD3ζ by shRNA as a platform to develop allogeneic CAR T cell therapy

The targeted knockdown of CD3ζ by shRNA as a platform to develop allogeneic CAR T cell therapy

Celyad Announces Pricing of $20.0 Million Global Offering

Celyad Announces Pricing of $20.0 Million Global Offering

Celyad Announces Launch of Proposed Global Offering

Celyad Announces Launch of Proposed Global Offering

Celyad Successfully Doses First Patient with CYAD-01 Produced with OptimAb Manufacturing Process

Celyad Successfully Doses First Patient with CYAD-01 Produced with OptimAb Manufacturing Process

Celyad to Participate in Upcoming September 2019 Conferences

Celyad to Participate in Upcoming September 2019 Conferences

Celyad Reports Half Year 2019 Financial Results and Second Quarter Business Highlights

Celyad Reports Half Year 2019 Financial Results and Second Quarter Business Highlights

Celyad to Provide First Half 2019 Financial Results & Business Highlights and Host a Conference Call

Celyad to Provide First Half 2019 Financial Results & Business Highlights and Host a Conference Call

Phase 1 studies assessing the safety and clinical activity of autologous and allogeneic NKG2D-based CAR T therapy in metastatic colorectal cancer

Phase 1 studies assessing the safety and clinical activity of autologous and allogeneic NKG2D-based CAR T therapy in metastatic colorectal cancer